No request received yet for EU authorisation of Covishield: official

Meanwhile, the 27-member European bloc is now introducing the EU Digital Covid Certificate, which is meant to facilitate safe free movement during the Covid-19 pandemic within the EU.

Covishield
Covishield (Photo: PTI)
ANI Europe
3 min read Last Updated : Jun 29 2021 | 4:10 PM IST

A European Union (EU) official on Tuesday said that the European Medicines Agency (EMA) has not received any request for approval of authorisation of the COVID-19 vaccine, Covishield.

Speaking to ANI, the EU official said: "Concerning a possible EMA authorisation for Covishield, as of yesterday, the European Medicine Agency (EMA) stated that it had not received a request for approval. It will examine any such request when received, as per its procedures."

"The EMA does not investigate new drugs on its own, unless it is asked by the relevant companies," he said.

Meanwhile, the official said the member states of the bloc will gradually lift temporary travel restrictions for people from India at their external borders, based on the developments of the health situation pertaining to the COVID-19 pandemic.

"As to travel to the EU from India, temporary restrictions on non-essential travel to the EU are currently in place from many non-EU countries, including India, due to COVID. EU Member States shall gradually lift these temporary travel restrictions at the external borders, based on developments of the health situation," the EU official told ANI.

Meanwhile, the 27-member European bloc is now introducing the EU Digital COVID Certificate, which is meant to facilitate safe free movement during the COVID-19 pandemic within the EU.

The certificate will serve as evidence that a person was vaccinated against COVID-19, received a negative test result or recovered from COVID-19. The aim of the EU Digital COVID Certificate is to facilitate free movement inside the EU. It is not a pre-condition to travel.

For this purpose, member states of the EU will have the option to accept also vaccinations that have been authorised by the World Health Organization (WHO), including Covishield, confirmed the EU official.

On Monday, Adar Poonawalla, Chief Executive Officer (CEO) and owner of the Serum Institute of India (SII) assured Indians who have taken Covishield doses and are now facing issues while travelling to European Union countries that the matter had been escalated to the 'highest level'.

"I realise that a lot of Indians who have taken COVISHIELD are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," he tweeted.

This comes after reports that travellers vaccinated with Covishield, the AstraZeneca-Oxford vaccine manufactured in India by the SII, may not be eligible for the European Union's 'Green Pass'.

Europe's vaccine passport programme, which allowed recipients to travel to and from Europe with fewer roadblocks, may not recognise recipients of the Covishield vaccine.

Covishield is one of the three COVID-19 vaccines approved for use in India.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusEuropean UnionCoronavirus Vaccine

First Published: Jun 29 2021 | 4:07 PM IST

Next Story